Placeholder Banner

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

October 8, 2014
Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock's portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product and alliance leader for VELCADE. Mr. Leschly also founded and serves as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his M.B.A. from Wharton Business School. He currently serves as a member of the Biotechnology Industry Organization board.

Chris Collins of Piper Jaffray moderated a fireside chat with Leschly at the 2014 BIO Investor Forum. They discussed Leschly's background in venture capital, gene therapy, and his personal experiences and lessons learned from blueblurb bio's IPO.

Leschly also participated in a BIO Buzz Center interview with biotechnology journalist Luke Timmerman.